Literature DB >> 1361193

Thyroid stimulatory autoantibodies in different patients with autoimmune thyroid disease do not all recognize the same components of the human thyrotropin receptor: selective role of receptor amino acids Ser25-Glu30.

Y Nagayama1, B Rapoport.   

Abstract

To study the interaction between TSH, autoantibodies and the amino-terminal half of the TSH receptor extracellular region (amino acids 1-260; domains ABC), we constructed 20 LH/CG chimeric receptor cDNAs. The prototypic receptor for modification contained domains ABC of the TSH receptor and domains DE of the LH/CG receptor. Segments (6-13 amino acids) within the ABC domains were replaced with the corresponding amino acids of the rat LH/CG receptor. Fifteen of the 20 chimeric receptors could be expressed functionally in Chinese hamster ovary cells. Twelve retained both high affinity TSH binding and normal signal transduction. These 12 receptors were tested with a panel of 10 patients' immunoglobulin G (IgG) samples containing potent TSH receptor stimulatory activity. With 11 of the receptor variants, the cAMP responses were similar to those with the prototype receptor (TSH-LHR-6). However, the -A1 variant of TSH-LHR-6 (Ser25-Glu30) responded poorly to 6 of 10 IgGs. The same pattern was observed when the IgGs were tested for their ability to inhibit [125I] TSH binding to the receptor variants, suggesting qualitative differences between the different stimulatory TSH receptor autoantibodies. Therefore, we examined the dose-response relationship of 2 IgGs that were approximately equipotent when tested with TSH-LHR-6 and its -A1 variant and another 2 IgGs that displayed greatly diminished potency with respect to the -A1 variant. Despite dilution to nearly undetectable levels, the relative potencies of the 4 IgG samples for both types of receptors remained similar. These data demonstrate directly that stimulatory TSH receptor autoantibodies do not all recognize the same components of the TSH receptor. The segment of the TSH receptor discriminated by these autoantibodies is between amino acids Ser25-Glu30.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1361193     DOI: 10.1210/jcem.75.6.1361193

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  9 in total

1.  Insight into thyroid-stimulating autoantibody interaction with the thyrotropin receptor N-terminus based on mutagenesis and re-evaluation of ambiguity in this region of the receptor crystal structure.

Authors:  Sepehr Hamidi; Chun-Rong Chen; Sandra M McLachlan; Basil Rapoport
Journal:  Thyroid       Date:  2011-08-11       Impact factor: 6.568

2.  Unaltered thyroid function in mice responding to a highly immunogenic thyrotropin receptor: implications for the establishment of a mouse model for Graves' disease.

Authors:  G Carayanniotis; G C Huang; L B Nicholson; T Scott; P Allain; A M McGregor; J P Banga
Journal:  Clin Exp Immunol       Date:  1995-02       Impact factor: 4.330

3.  Thyroid-stimulating autoantibodies in Graves disease preferentially recognize the free A subunit, not the thyrotropin holoreceptor.

Authors:  Gregorio D Chazenbalk; Pavel Pichurin; Chun-Rong Chen; Francesco Latrofa; Alan P Johnstone; Sandra M McLachlan; Basil Rapoport
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

4.  Evidence that factors other than particular thyrotropin receptor T cell epitopes contribute to the development of hyperthyroidism in murine Graves' disease.

Authors:  P N Pichurin; Chun-Rong Chen; Y Nagayama; O Pichurina; B Rapoport; S M McLachlan
Journal:  Clin Exp Immunol       Date:  2004-03       Impact factor: 4.330

5.  The superagonistic activity of bovine thyroid-stimulating hormone (TSH) and the human TR1401 TSH analog is determined by specific amino acids in the hinge region of the human TSH receptor.

Authors:  Sandra Mueller; Gunnar Kleinau; Mariusz W Szkudlinski; Holger Jaeschke; Gerd Krause; Ralf Paschke
Journal:  J Biol Chem       Date:  2009-04-22       Impact factor: 5.157

6.  Evidence that shed thyrotropin receptor A subunits drive affinity maturation of autoantibodies causing Graves' disease.

Authors:  Yumiko Mizutori; Chun-Rong Chen; Francesco Latrofa; Sandra M McLachlan; Basil Rapoport
Journal:  J Clin Endocrinol Metab       Date:  2008-12-09       Impact factor: 5.958

7.  Probing structural variability at the N terminus of the TSH receptor with a murine monoclonal antibody that distinguishes between two receptor conformational forms.

Authors:  Sepehr Hamidi; Chun-Rong Chen; Ramachandran Murali; Sandra M McLachlan; Basil Rapoport
Journal:  Endocrinology       Date:  2012-11-26       Impact factor: 4.736

8.  Antibodies to TSH-receptor in thyroid autoimmune disease interact with monoclonal antibodies whose epitopes are broadly distributed on the receptor.

Authors:  W B Minich; C Lenzner; N G Morgenthaler
Journal:  Clin Exp Immunol       Date:  2004-04       Impact factor: 4.330

9.  Clinical significance of classification of Graves' disease according to the characteristics of TSH receptor antibodies.

Authors:  W B Kim; H K Chung; Y J Park; D J Park; H K Lee; B Y Cho
Journal:  Korean J Intern Med       Date:  2001-09       Impact factor: 2.884

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.